CD79A and nasopharyngeal carcinoma: Since serum EBV EBNA-1 and VCA-IgA antibodies can be detected in 3–5 years before the diagnosis of NPC and have been widely used for NPC screening in mainland China and Taiwan, these donors were categorized as a high-risk population for the development of NPC [45,46,47].